Your browser doesn't support javascript.
loading
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.
Casartelli, C; Tommasi, C; Lazzarin, A; Corianò, M; Tornali, C; Serra, O; Campanini, N; Gutiérrez-Enríquez, S; Sikokis, A; Zanoni, D; Minari, R; Bortesi, B; Michiara, M; Boggiani, D; Uliana, V; Llop-Guevara, A; Serra, V; Musolino, A; Pellegrino, B.
Afiliação
  • Casartelli C; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
  • Tommasi C; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
  • Lazzarin A; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
  • Corianò M; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
  • Tornali C; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Serra O; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
  • Campanini N; Pathology Unit, University Hospital of Parma, Parma, Italy.
  • Gutiérrez-Enríquez S; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Sikokis A; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
  • Zanoni D; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
  • Minari R; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Bortesi B; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Michiara M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
  • Boggiani D; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
  • Uliana V; Medical Genetics Unit, University Hospital of Parma, Parma, Italy.
  • Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Musolino A; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy. Electronic address: antonino.musolino@unipr.it.
  • Pellegrino B; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.
ESMO Open ; 9(7): 103629, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38970842

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dano ao DNA / Proteína BRCA1 / Rad51 Recombinase Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dano ao DNA / Proteína BRCA1 / Rad51 Recombinase Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article